~~<i id='B15F963EFB'><strike id='B15F963EFB'><tt id='B15F963EFB'><pre id='B15F963EFB'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：knowledge 2025-08-10 09:23:44 Page View：23

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ARCH Venture Partners tops STAT's 2023 biotech VC rankings
Next article： Sports medicine is finally prioritizing gender equality

focus

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

FDA seeking to stop procedures at two unregulated stem cell clinics

StemcellsSpencerPlatt/GettyImagesFederalofficialsmovedonWednesdaytostoptwoclinicsfromcontinuingtooff

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Johnson & Johnson sues to stop Medicare negotiation

MARKRALSTON/AFPviaGettyImagesWASHINGTON— PharmaceuticalgiantJohnson&JohnsononTuesdaybecamethethi